首页> 外文期刊>CNS spectrums >Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia
【24h】

Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia

机译:每月帕利维酮棕榈酸盐与精神分裂症患者的常规和非典型日常口服抗精神病治疗相比

获取原文
获取原文并翻译 | 示例
       

摘要

Objective This analysis of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study (NCT01157351) compared outcomes after administration of once-monthly paliperidone palmitate (PP) vs conventional oral antipsychotics (COAs) or atypical oral antipsychotics (AOAs).
机译:目的对帕帕里酮棕榈酸棕榈酸族研究(NCT01157351)对常规口服抗精神病药(COAS)或非典型口服抗精神病药(AOAs)进行术后掌上术语(NCT01157351)对疗效(NCT01157351)比较结果的影响

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号